A detailed history of Warberg Asset Management LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Warberg Asset Management LLC holds 39,000 shares of ANVS stock, worth $57,720. This represents 0.63% of its overall portfolio holdings.

Number of Shares
39,000
Holding current value
$57,720
% of portfolio
0.63%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025

BUY
$1.5 - $5.39 $58,500 - $210,210
39,000 New
39,000 $58,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $12.1M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Warberg Asset Management LLC Portfolio

Follow Warberg Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Warberg Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Warberg Asset Management LLC with notifications on news.